Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Takeshi Takamoto

Matched on ORCID iD 0000-0003-0455-6412; OpenAlex author ID A5014166430, A5087217398. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2022: 2 papers · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Co-author DOI 10.1016/j.hpb.2025.12.021↗
  2. Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? Co-author DOI 10.1245/s10434-025-18511-2↗
  3. Neoadjuvant gemcitabine and S-1 in pancreatic ductal adenocarcinoma: Effects on nutritional status and pancreaticoduodenectomy outcomes. Co-author DOI 10.1016/j.surg.2024.109026↗
  4. Oligo-like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer. Co-author DOI 10.1002/ags3.12753↗
  5. Safety and feasibility of percutaneous abdominal lavage cytology screening (PACS) prior to surgical resection for pancreatic cancer. Co-author DOI 10.1007/s00261-024-04510-6↗
  6. [A case of R0 resection in conversion surgery after duodenal stent placement for locally advanced unresectable pancreatic cancer with duodenal stenosis]. Co-author DOI 10.11405/nisshoshi.121.407↗
  7. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11950-1↗
  8. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11957-8↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Nara · 5 shared papers, 2022–2025 · strength 1.02
  2. Daisuke Ban · 5 shared papers, 2022–2025 · strength 1.02
  3. Minoru Esaki · 5 shared papers, 2022–2025 · strength 1.02
  4. Sho Kiritani · 2 shared papers, 2026 · strength 0.55
  5. Yusuke Kazami · 2 shared papers, 2026 · strength 0.55
  6. Satoru Abe · 2 shared papers, 2026 · strength 0.55
  7. Kiyoshi Hasegawa · 2 shared papers, 2026 · strength 0.55
  8. Kazuaki Shimada · 3 shared papers, 2022–2024 · strength 0.54
  9. Shunsuke Sugawara · 3 shared papers, 2022–2024 · strength 0.48
  10. Kei Kitamura · 2 shared papers, 2022 · strength 0.30
  11. Nobuyoshi Hiraoka · 2 shared papers, 2022 · strength 0.30
  12. Kazunaga Ishigaki · 1 shared paper, 2026 · strength 0.26
  13. Naminatsu Takahara · 1 shared paper, 2026 · strength 0.26
  14. Tatsunori Suzuki · 1 shared paper, 2026 · strength 0.26
  15. Mitsuhiro Fujishiro · 1 shared paper, 2026 · strength 0.26
  16. Ryo Saito · 1 shared paper, 2024 · strength 0.24
  17. Hirokazu Komatsu · 1 shared paper, 2024 · strength 0.21
  18. Yuta Iwai · 1 shared paper, 2024 · strength 0.21
  19. Mizuki Ozawa · 1 shared paper, 2024 · strength 0.18
  20. Ryosuke Umino · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.